Form 4: SpringWorks Therapeutics Completes Acquisition by Merck KGaA, Director Disposes of Shares

SpringWorks Therapeutics, Inc. has completed its merger with Merck KGaA, Darmstadt, Germany, resulting in the conversion of all outstanding shares, restricted stock units, and stock options into cash or cash-based awards.

Summary

• SpringWorks Therapeutics, Inc. (SWTX) completed its merger with Merck KGaA, Darmstadt, Germany, effective July 1, 2025.
• Freda C. Lewis-Hall, a Director of SpringWorks Therapeutics, Inc., reported the disposition of her beneficial ownership in the company due to the merger.
• At the effective time of the merger, each outstanding share of SpringWorks Therapeutics common stock was cancelled and automatically converted into the right to receive $47.00 in cash per share.
• A total of 24,727 shares of common stock, including 10,060 shares underlying restricted stock units (RSUs), were disposed of by the reporting person.
• Outstanding RSUs, whether vested or unvested, were cancelled and converted into cash-based RSU awards, with a value equal to the merger consideration multiplied by the number of shares subject to the RSU.
• Vested outstanding stock options were cancelled and converted into cash, calculated as the product of the number of shares subject to the option and the excess of the merger consideration ($47.00) over the option's exercise price.
• Unvested outstanding stock options were cancelled and converted into Parent Cash-Based Option Awards, with a value calculated similarly to vested options.
• Parent Cash-Based RSU Awards and Option Awards will generally vest according to their original terms, with a provision for 50% of each then-unvested tranche to vest on the nine-month anniversary of the closing date, subject to continued employment.
• Stock options with an exercise price greater than $47.00 per share were cancelled for no consideration or payment.
• The reporting person disposed of stock options with exercise prices ranging from $18.00 to $44.77, totaling 78,775 options.

Sentiment

Score: 7

Explanation: The document reports the successful completion of a merger, resulting in a cash payout for shareholders and conversion of equity awards, which is generally a positive outcome for the exiting shareholders and employees with continued vesting.

Positives

• Shareholders of SpringWorks Therapeutics received a cash payout of $47.00 per share, providing a clear exit value.
• Employees with unvested restricted stock units and stock options had their awards converted into cash-based awards, maintaining a path to value realization post-merger, subject to continued employment.
• The merger provides a definitive outcome for the company and its investors.

Negatives

• Stock options with an exercise price greater than the $47.00 merger consideration were cancelled for no value, resulting in a loss for holders of those specific options.
• SpringWorks Therapeutics, Inc. is no longer an independent publicly traded company, becoming a wholly owned subsidiary of Merck KGaA.

Risks

• Continued vesting of Parent Cash-Based RSU Awards and Option Awards for employees is subject to their continued employment with Parent through the specified vesting dates.
• All cash payments are subject to any required tax withholding.

Future Outlook

SpringWorks Therapeutics, Inc. is now a wholly owned subsidiary of Merck KGaA, Darmstadt, Germany. The future outlook for the entity is integrated with that of its new parent company. Unvested cash-based RSU and option awards will continue to vest according to their original terms, with a specific acceleration clause for 50% vesting on the nine-month anniversary of the merger closing, contingent on continued employment.

Industry Context

This transaction reflects a broader trend of consolidation within the biotechnology and pharmaceutical sectors, where larger pharmaceutical companies acquire innovative biotech firms to expand their pipelines and market presence. The acquisition of SpringWorks Therapeutics by Merck KGaA aligns with strategies to integrate promising therapeutic assets.

Corporate Governance

Stakeholder Impact

• Shareholders: Received $47.00 in cash per share for their common stock holdings.
• Employees: Those with unvested RSUs and stock options had their awards converted into cash-based awards, with continued vesting contingent on employment, providing a retention mechanism post-merger.
• Creditors: No direct impact mentioned, but the company's financial backing is now tied to Merck KGaA.

Next Steps

• Continued vesting of Parent Cash-Based RSU Awards and Parent Cash-Based Option Awards for eligible employees, subject to continued employment.

Key Dates

Keywords

SpringWorks Therapeutics, SWTX, Merck KGaA, Merger, Acquisition, Form 4, Insider Trading, Stock Options, Restricted Stock Units, Beneficial Ownership, Corporate Action